Get started
ULTRAGENYX PHARMACEUTICAL INC COM USD0.001ULTRAGENYX PHARMACEUTICAL INC COM USD0.001ULTRAGENYX PHARMACEUTICAL INC COM USD0.001

ULTRAGENYX PHARMACEUTICAL INC COM USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0LIF chart


Full chart

0LIF upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.28 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.3 USD
Net income (FY)
‪−569.18 M‬ USD
Revenue (FY)
‪560.23 M‬ USD
Shares float
‪87.56 M‬
Beta (1Y)
1.14

Employees


Employees (FY)
‪1.29 K‬
Change (1Y)
+18 +1.41%
Revenue / Employee (1Y)
‪432.94 K‬ USD
Net income / Employee (1Y)
‪−439.86 K‬ USD

About Ultragenyx Pharmaceutical Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Emil D. Kakkis
Website
ultragenyx.com
Headquarters
Novato
Founded
2010
FIGI
BBG00JVXHH87
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0LIF news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as 0LIF.

Frequently Asked Questions


The current price of 0LIF is 35.7 USD — it has increased by 3.84% in the past 24 hours. Watch ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 stocks are traded under the ticker 0LIF.
0LIF stock has risen by 7.41% compared to the previous week, the month change is a −8.44% fall, over the last year ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 has showed a −15.57% decrease.
We've gathered analysts' opinions on ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 future price: according to them, 0LIF price has a max estimate of 140.00 USD and a min estimate of 39.00 USD. Watch 0LIF chart and read a more detailed ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 stock forecast: see what analysts think of ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 and suggest that you do with its stocks.
0LIF reached its all-time high on Feb 9, 2021 with the price of 169.2 USD, and its all-time low was 30.0 USD and was reached on Apr 9, 2025. View more price dynamics on 0LIF chart.
See other stocks reaching their highest and lowest prices.
0LIF stock is 3.72% volatile and has beta coefficient of 1.14. Track ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 stock price on the chart and check out the list of the most volatile stocks — is ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 there?
Today ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 has the market capitalization of ‪3.35 B‬, it has increased by 4.22% over the last week.
Yes, you can track ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 financials in yearly and quarterly reports right on TradingView.
ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
0LIF earnings for the last quarter are −1.39 USD per share, whereas the estimation was −1.31 USD resulting in a −6.23% surprise. The estimated earnings for the next quarter are −1.60 USD per share. See more details about ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 earnings.
ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 revenue for the last quarter amounts to ‪164.88 M‬ USD, despite the estimated figure of ‪151.86 M‬ USD. In the next quarter, revenue is expected to reach ‪143.82 M‬ USD.
0LIF net income for the last quarter is ‪−133.38 M‬ USD, while the quarter before that showed ‪−133.52 M‬ USD of net income which accounts for 0.098% change. Track more ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 financial stats to get the full picture.
No, 0LIF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has ‪1.29 K‬ employees. See our rating of the largest employees — is ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 EBITDA is ‪−500.43 M‬ USD, and current EBITDA margin is −89.33%. See more stats in ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 financial statements.
Like other stocks, 0LIF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 stock shows the sell signal. See more of ULTRAGENYX PHARMACEUTICAL INC COM USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.